Metraipolis › archive › dc_27e4e506ea18

TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer — Europe PMC PMID:41187938

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41187938
DOI: 10.1002/cnr2.70394
License (as archived): solo-consultazione
Archived: 2026-11-08T21:16:49.283Z
SHA-256 of the archived text: de0d3a0298a037c483d2b275b8beed17086dcb7b9c54258a5b16b107fc6862d6
Stable URL of this page: https://metraipolis.com/documento/dc_27e4e506ea18

How to cite

TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer — Europe PMC PMID:41187938 — Europe PMC (en), https://europepmc.org/article/MED/41187938 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_27e4e506ea18 (Metraipolis archive dc_27e4e506ea18, sha256 de0d3a0298a037c483d2b275b8beed17086dcb7b9c54258a5b16b107fc6862d6)

BibTeX

@misc{dc27e4e506ea18,
  title = {TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer — Europe PMC PMID:41187938},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41187938},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_27e4e506ea18; sha256 de0d3a0298a037c483d2b275b8beed17086dcb7b9c54258a5b16b107fc6862d6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41187938. Agents can read the archived copy with the MCP tool read_document.